Answers are grounded in this paper and cite their sources.
Fiducial marker implantation for tumor localization in radiotherapy is effective but invasive and carries complication risks. To address this, we propose a marker-less tumor tracking framework to explore the feasibility of a cross-patient deep learning model, aiming to eliminate the need for per-patient retraining. A novel degradation model generates realistic simulated data from digitally reconstructed radiographs (DRRs) to train a Restormer network, which transforms clinical fluoroscopic images into clean, DRR-like images. Subsequently, a DUCK-Net model, trained on DRRs, performs tumor segmentation. We conducted a feasibility study using a clinical dataset from 7 lung cancer patients, comprising 100 distinct treatment fields. The framework achieved an average processing time of 179.8 ms per image and demonstrated high accuracy: the median 3D Euclidean tumor center tracking error was 1.53 mm, with directional errors of 0.98±0.70 mm (LR), 1.09±0.74 mm (SI), and 1.34±0.94 mm (AP). These promising results validate our approach as a proof-of-concept for a cross-patient marker-less tumor tracking solution, though further large-scale validation is required to confirm broad clinical applicability.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: